ahlam1399
06-04-2015, 09:46 AM
BRIEF-Vexim initiates clinical study assessing safety and efficacy of SpineJack
* Initiates international clinical study with first patient treated to support planned 510(k) application to market SpineJack in the United Stateshttp://i1.wp.com/reuters.us.feedsportal.com/c/35217/f/654213/s/46eb26d8/sc/33/mf.gif?resize=1%2C1
http://da.feedsportal.com/r/230959970643/u/49/f/654213/c/35217/s/46eb26d8/sc/33/rc/1/rc.img (http://da.feedsportal.com/r/230959970643/u/49/f/654213/c/35217/s/46eb26d8/sc/33/rc/1/rc.htm)
http://da.feedsportal.com/r/230959970643/u/49/f/654213/c/35217/s/46eb26d8/sc/33/rc/2/rc.img (http://da.feedsportal.com/r/230959970643/u/49/f/654213/c/35217/s/46eb26d8/sc/33/rc/2/rc.htm)
http://da.feedsportal.com/r/230959970643/u/49/f/654213/c/35217/s/46eb26d8/sc/33/rc/3/rc.img (http://da.feedsportal.com/r/230959970643/u/49/f/654213/c/35217/s/46eb26d8/sc/33/rc/3/rc.htm)
http://da.feedsportal.com/r/230959970643/u/49/f/654213/c/35217/s/46eb26d8/sc/33/a2.img (http://da.feedsportal.com/r/230959970643/u/49/f/654213/c/35217/s/46eb26d8/sc/33/a2.htm)
http://adchoice.feedsportal.com/r/230959970643/u/49/f/654213/c/35217/s/46eb26d8/sc/33/ach.img (http://adchoice.feedsportal.com/r/230959970643/u/49/f/654213/c/35217/s/46eb26d8/sc/33/ach.htm)http://pi.feedsportal.com/r/230959970643/u/49/f/654213/c/35217/s/46eb26d8/sc/33/a2t.imghttp://pi2.feedsportal.com/r/230959970643/u/49/f/654213/c/35217/s/46eb26d8/sc/33/a2t2.imghttp://feeds.feedburner.com/~ff/reuters/companyNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/companyNews?a=wEQpOkLP7T4:H3ADyIoBs3o:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/companyNews?i=wEQpOkLP7T4:H3ADyIoBs3o:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/companyNews?a=wEQpOkLP7T4:H3ADyIoBs3o:V_sGLiPBpWU) http://feeds.feedburner.com/~ff/reuters/companyNews?i=wEQpOkLP7T4:H3ADyIoBs3o:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/companyNews?a=wEQpOkLP7T4:H3ADyIoBs3o:F7zBnMyn0Lo)
http://feeds.feedburner.com/~r/reuters/companyNews/~4/wEQpOkLP7T4
* Initiates international clinical study with first patient treated to support planned 510(k) application to market SpineJack in the United Stateshttp://i1.wp.com/reuters.us.feedsportal.com/c/35217/f/654213/s/46eb26d8/sc/33/mf.gif?resize=1%2C1
http://da.feedsportal.com/r/230959970643/u/49/f/654213/c/35217/s/46eb26d8/sc/33/rc/1/rc.img (http://da.feedsportal.com/r/230959970643/u/49/f/654213/c/35217/s/46eb26d8/sc/33/rc/1/rc.htm)
http://da.feedsportal.com/r/230959970643/u/49/f/654213/c/35217/s/46eb26d8/sc/33/rc/2/rc.img (http://da.feedsportal.com/r/230959970643/u/49/f/654213/c/35217/s/46eb26d8/sc/33/rc/2/rc.htm)
http://da.feedsportal.com/r/230959970643/u/49/f/654213/c/35217/s/46eb26d8/sc/33/rc/3/rc.img (http://da.feedsportal.com/r/230959970643/u/49/f/654213/c/35217/s/46eb26d8/sc/33/rc/3/rc.htm)
http://da.feedsportal.com/r/230959970643/u/49/f/654213/c/35217/s/46eb26d8/sc/33/a2.img (http://da.feedsportal.com/r/230959970643/u/49/f/654213/c/35217/s/46eb26d8/sc/33/a2.htm)
http://adchoice.feedsportal.com/r/230959970643/u/49/f/654213/c/35217/s/46eb26d8/sc/33/ach.img (http://adchoice.feedsportal.com/r/230959970643/u/49/f/654213/c/35217/s/46eb26d8/sc/33/ach.htm)http://pi.feedsportal.com/r/230959970643/u/49/f/654213/c/35217/s/46eb26d8/sc/33/a2t.imghttp://pi2.feedsportal.com/r/230959970643/u/49/f/654213/c/35217/s/46eb26d8/sc/33/a2t2.imghttp://feeds.feedburner.com/~ff/reuters/companyNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/companyNews?a=wEQpOkLP7T4:H3ADyIoBs3o:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/companyNews?i=wEQpOkLP7T4:H3ADyIoBs3o:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/companyNews?a=wEQpOkLP7T4:H3ADyIoBs3o:V_sGLiPBpWU) http://feeds.feedburner.com/~ff/reuters/companyNews?i=wEQpOkLP7T4:H3ADyIoBs3o:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/companyNews?a=wEQpOkLP7T4:H3ADyIoBs3o:F7zBnMyn0Lo)
http://feeds.feedburner.com/~r/reuters/companyNews/~4/wEQpOkLP7T4